Zenas BioPharma surges 10.43% premarket after major fundraising and CEO/Director share purchases signal confidence.

Zenas BioPharma jumped 10.43% in premarket trading, likely driven by news that the company raised $287.5 million through a mix of convertible notes and equity. The fundraising includes $200 million in 2.50% convertible senior notes and 5 million shares sold at $20 each, improving liquidity and addressing prior concerns about its financial runway. Additionally, the company’s multiple sclerosis drug, obexelimab, showed a 95% reduction in brain lesions in a Phase 2 trial, reinforcing its clinical development profile. CEO Leon Moulder’s recent large share purchases also signaled confidence in the stock’s long-term potential. These developments collectively contributed to the premarket rally.